Login to Your Account



OTHER NEWS TO NOTE


Wednesday, May 31, 1995

No Abstract

* XOMA Corp., of Berkeley, Calif., received FDA clearance to start a Phase II trial of Neuprex (rBPI-21), for treatment of trauma patients suffering complications associated with hemorrhagic trauma. (See BioWorld Today, May 11, 1995, p. 1.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription